arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Mirum Pharmaceuticals, Inc.

MIRM
$89.35 ▼ -2.07 (-2.26%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Bearish
auto_awesome

Analytical Summary

Mirum Pharmaceuticals, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.7B
Dividend Yield —
Revenue Growth 37.9% ↘
Op. Margin -24.1% ↗
ROIC 418.7% ↗
FCF / Share $-0.70 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$176.24M
↑ +37.9% —
Net Income Profit after all expenses
$-790.15M
↓ -5283.6% —
Operating Margin Operating profit as % of sales
-24.1%
↑ +95.1% 21th
FCF / Share Free cash flow per share
$-0.70
↑ +82.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
35
Returns ↑
36
Financial Health ↑
43
Cash Quality
6

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters